Turn Therapeutics Reports Third-Quarter Loss of $6.23 Million

Turn Therapeutics reported a third-quarter 2026 net loss of $6.2 million, or $0.21 per share, and had $10.4 million in cash and cash equivalents at September 30. The company said its cash is expected to fund operations into the third quarter of 2027. It also reported progress in its atopic dermatit…